Sandoz Can't Cancel Sanofi Unit's Autoimmune Disorder Drug
European appellate officials have upheld a Sanofi unit's patent for a drug treating autoimmune disorders despite objections from Sandoz because the specific enzyme blockers it uses were structurally different from those...To view the full article, register now.
Already a subscriber? Click here to view full article